Consent given pursuant to sections 14 and 14A to the supply of the therapeutic goods specified - iNova Pharmaceuticals

Overview

The Therapeutic Goods Act 1989 (the Act) was enacted to regulate the importation, supply, and manufacturing of therapeutic goods in Australia, ensuring that they are of acceptable quality, efficacy, and safety. The Act was introduced to address the need for a comprehensive legislative framework that governs the oversight of therapeutic products, including medicines, medical devices, and other related goods. Enacted by the Australian Parliament, the Act aims to protect public health by ensuring that therapeutic goods available in the Australian market meet certain standards and are safe for use. This legislative framework is critical in maintaining public confidence in the health system and ensuring that therapeutic goods are appropriately regulated to prevent harm to consumers. In a specific instance, on 11 August 2015, the Secretary of the Department of Health granted consent under sections 14 and 14A of the Therapeutic Goods Act 1989 to iNova Pharmaceuticals Australia Pty Ltd for the supply of NYAL ANTIVIRAL COLD SORE CREAM, which did not conform to the microbiological standards set out in Therapeutic Goods Order No. 77. This consent was subject to certain conditions, including compliance with the United States Pharmacopeia General Chapter <51> Antimicrobial Effectiveness Testing and other British Pharmacopoeia requirements, effective from 11 August 2015 until 30 November 2016. This case highlights the Act's role in allowing exceptions under strict regulatory oversight to ensure that therapeutic goods can be made available to the public when necessary, provided that safety and quality standards are maintained.

Scope and Application

The Therapeutic Goods Act 1989 applies to therapeutic goods, including medicines, medical devices, and other health-related products, within the jurisdiction of the Commonwealth of Australia. The Act regulates the importation, supply, and monitoring of these goods to ensure they meet safety, quality, and efficacy standards. The Act applies to individuals and entities such as manufacturers, suppliers, and distributors involved in the supply chain of therapeutic goods. The scope of the Act extends to the entire nation, providing a consistent regulatory framework across Australia. Notably, the Act includes provisions for exclusions and exemptions, allowing certain goods or activities to be exempt from certain regulatory requirements. The Act's application can be further refined or expanded through subordinate instruments, such as regulations and orders, which provide detailed specifications and standards for different types of therapeutic goods. In this specific instance, the Act facilitated a consent for the supply of a non-compliant pharmaceutical product under strict conditions to address a temporary shortfall in meeting the required microbiological standards.

Key Provisions

Sections 14 and 14A of the Therapeutic Goods Act 1989 (the Act) provide mechanisms through which the Secretary of the Department of Health may consent to the supply of therapeutic goods that do not conform to certain regulatory standards, provided that specific conditions are met. Under these sections, iNova Pharmaceuticals Australia Pty Ltd applied for and received consent to supply NYAL ANTIVIRAL COLD SORE CREAM (AUST R 147218), a product that does not meet the microbiological standards outlined in Therapeutic Goods Order No. 77. This consent, effective from 11 August 2015 until 30 November 2016, allows the product to be supplied under certain specified conditions designed to mitigate any risks associated with its non-compliance. The obligations imposed by the consent under sections 14 and 14A require iNova Pharmaceuticals to ensure that the product meets the acceptance criteria for Aspergillus brasiliensis as specified in the USP General Chapter <51> Antimicrobial Effectiveness Testing. Additionally, the product must adhere to all other requirements of the British Pharmacopoeia Test for Efficacy of Antimicrobial Preservation. These conditions are intended to safeguard public health by ensuring that the product maintains a certain level of efficacy and safety despite its non-compliance with some regulatory standards. Failure to meet the conditions stipulated in the consent may have serious consequences. Under the Act, breaches of the conditions may result in enforcement actions. While specific penalties are not detailed in the notice, breaches of the Therapeutic Goods Act can generally lead to both civil and criminal penalties. Civil penalties can include fines up to a significant amount, depending on the severity and frequency of the breach. Criminal penalties may include fines and imprisonment, with the exact penalties varying according to the specific provision of the Act that has been contravened. The Therapeutic Goods Act provides a framework for the regulation of therapeutic goods in Australia, and adherence to the conditions of consent is critical to avoid these legal repercussions.